Corpus overview


MeSH Disease

Infections (587)

Disease (522)

Coronavirus Infections (347)

Death (195)

Pneumonia (179)

Human Phenotype

Pneumonia (195)

Fever (141)

Cough (103)

Hypertension (91)

Respiratory distress (64)


    displaying 621 - 630 records in total 1218
    records per page

    Improved detection of antibody SERO against SARS-CoV-2 by microsphere-based antibody SERO assay

    Authors: Carol Ho Yan Fong; Thrimendra Kaushika Dissanayake; Lin-Lei Chen; Charlotte Yee-Ki Choi; Lok-Hin Wong; Anthony Chin-Ki Ng; Polly K.P Pang; Deborah Tip-Yin Ho; Rosana Wing-Shan Poon; Tom Wai-Hin Chung; Siddharth Sridhar; Kwok-Hung Chan; Jasper Fuk-Woo Chan; Ivan Fan-Ngai Hung; Kwok-Yung Yuen; Kelvin Kai-Wang To

    doi:10.1101/2020.05.26.20113191 Date: 2020-05-26 Source: medRxiv

    Objective: Currently available COVID-19 antibody tests SERO using enzyme immunoassay SERO (EIA) or immunochromatographic assay have variable sensitivity SERO and specificity. Here, we developed and evaluated a novel microsphere-based antibody SERO assay (MBA) for the detection of immunoglobulin G (IgG) against SARS-CoV-2 nucleoprotein (NP) and spike protein receptor binding domain (RBD). Method: We developed a microsphere-based assay (MBA) to determine the levels of IgG against SARS-CoV-2 NP and spike RBD. The seropositive cut-off mean fluorescent intensity (MFI) was set using a cohort of 294 anonymous serum SERO specimens collected in 2018. The specificity was assessed using serum SERO specimens collected from organ donors or influenza patients before 2020. Seropositive rate was determined among patients with COVID-19. Time-to-seropositivity and signal-to-cutoff (S/CO) ratio were compared between MBA and EIA. Results: MBA had a specificity of 100% (93/93; 95% confidence interval [CI], 96-100%) for anti-NP IgG and 98.9% (92/93; 95% CI 94.2-100%) for anti-RBD IgG. The MBA seropositive rate for convalescent serum SERO specimens of COVID-19 patients were 89.8% (35/39) for anti-NP IgG and 79.5% (31/39) for anti-RBD IgG. The time-to-seropositivity was shorter with MBA than that of EIA. When compared with EIA, MBA could better differentiate between COVID-19 patients and negative controls with significantly higher S/CO ratio for COVID-19 patients and lower S/CO ratio with negative controls. MBA also had fewer specimens in the equivocal range (S/CO 0.9-1.1) than EIA. Conclusion: MBA is robust and simple, and is suitable for clinical microbiology laboratory for the accurate determination of anti- SARS-CoV-2 antibody SERO for retrospective diagnosis, serosurveillance, and vaccine trials.

    Single-Cell Analysis Reveals Macrophage-Driven T Cell Dysfunction in Severe COVID-19 Patients

    Authors: Xiaoqing Liu; Airu Zhu; Jiangping He; Zhao Chen; Longqi Liu; Yuanda Xu; Feng Ye; Huijian Feng; Lin Luo; Baomei Cai; Yuanbang Mai; Lihui Lin; Zhekun Zhang; Sibei Chen; Junjie Shi; Lilan Wen; Yuanjie Wei; Jianfen Zhuo; Yingying Zhao; Fang Li; Xiaoyu Wei; Dingbin Chen; Xinmei Zhang; Na Zhong; Yaling Huang; He Liu; Jinyong Wang; Xun Xu; Jie Wang; Ruchong Chen; Xinwen Chen; Nanshan Zhong; Jinxian Zhao; Yimin Li; Jincun Zhao; Jiekai Chen

    doi:10.1101/2020.05.23.20100024 Date: 2020-05-26 Source: medRxiv

    The vastly spreading COVID-19 pneumonia MESHD pneumonia HP is caused by SARS-CoV-2. Lymphopenia MESHD Lymphopenia HP and cytokine levels are tightly associated with disease MESHD severity. However, virus-induced immune dysregulation HP at cellular and molecular levels remains largely undefined. Here, the leukocytes in the pleural effusion MESHD pleural effusion HP, sputum, and peripheral blood SERO biopsies from severe and mild patients were analyzed at single-cell resolution. Drastic T cell hyperactivation accompanying elevated T cell exhaustion was observed, predominantly in pleural effusion MESHD pleural effusion HP. The mechanistic investigation identified a group of CD14+ monocytes and macrophages highly expressing CD163 and MRC1 in the biopsies from severe patients, suggesting M2 macrophage polarization. These M2-like cells exhibited up-regulated IL10, CCL18, APOE, CSF1 (M-CSF), and CCL2 signaling pathways. Further, SARS-CoV-2-specific T cells were observed in pleural effusion MESHD pleural effusion HP earlier than in peripheral blood SERO. Together, our results suggest that severe SARS-CoV-2 infection MESHD causes immune dysregulation HP by inducing M2 polarization and subsequent T cell exhaustion. This study improves our understanding of COVID-19 pathogenesis.

    Chansu Injection Improves the Respiratory Function of Severe COVID-19 Patients

    Authors: Fen Hu; Jiao Chen; Hao Chen; Jin Zhu; Chen Wang; Haibin Ni; Jianming Cheng; Peng Cao; Xingxing Hu

    doi:10.1101/2020.05.20.20107607 Date: 2020-05-26 Source: medRxiv

    Chansu and its major active constituent of bufalin have been reported to have broad-spectrum antiviral effects. This study aims to assess the efficacy of Chansu injection in treating patients with severe COVID-19. The patients diagnosed as severe or critical COVID-19 in The First People's Hospital of Jiangxia District, Wuhan, China from February 5 to March 5, 2020 were randomly allocated in a 1:1 ratio to receive general treatment plus Chansu injection or only general treatment as the control group. The treatment course was 7 days. The changes of PaO2/FiO2 and ROX index indicating respiratory function, the white blood SERO cell (WBC) count, peripheral blood SERO mononuclear lymphocyte (PBML) count, respiratory support step-down time (RSST), and safety indicators for the 7th day were retrospectively analyzed. After 7 days treatment, the oxygenation index was improved in 20 of 21 patients (95.2%) in the treatment group, as compared with 13 of 19 patients (68.4%) in the control group. The PaO2/FiO2 and ROX indices in the treatment group (mean, 226.27 and 14.01 respectively) were significantly higher than the control group (mean, 143.23 and 9.64 respectively). The RSST was 1 day shorter in the treatment group than the control group. Multivariate regression analysis suggested that Chansu injection contributed the most to the outcome of PaO2/FiO2. No obvious adverse effects were observed. Preliminary data showed that Chansu injection had apparent efficacy in treating patients with severe COVID-19.

    Prone Cardiopulmonary Resuscitation: A Rapid Scoping and Expanded Grey Literature Review for the COVID-19 Pandemic

    Authors: Matthew John Douma; Ella MacKenzie; Tess Loch; Maria C Tan; Dustin Anderson; Christopher Picard; Lazar Milovanovic; Domhnall O'Dochartaigh; Peter G Brindley

    doi:10.1101/2020.05.21.20109710 Date: 2020-05-26 Source: medRxiv

    Prone Cardiopulmonary Resuscitation: A Rapid Scoping and Expanded Grey Literature Review for the COVID-19 Pandemic Aim To rapidly identify and summarize the available science on prone resuscitation. To determine the value of undertaking a systematic review on this topic; and to identify knowledge gaps to aid future research, education and guidelines. Methods This review was guided by specific methodological framework and reporting items (PRISMA-ScR). We included studies, cases and grey literature regarding prone position and CPR/ cardiac arrest HP. The databases searched were MEDLINE, Embase, CINAHL, Cochrane CENTRAL, Cochrane Database of Systematic Reviews, Scopus and Google Scholar. Expanded grey literature searching included internet search engine, targeted websites and social media. Results Of 453 identified studies, 24 (5%) studies met our inclusion criteria. There were four prone resuscitation-relevant studies examining: blood SERO and tidal volumes generated by prone compressions; prone compression quality metrics on a manikin; and chest computed tomography scans for compression landmarking. Twenty case reports/series described the resuscitation of 25 prone patients. Prone compression quality was assessed by invasive blood SERO pressure monitoring, exhaled carbon dioxide and pulse palpation. Recommended compression location was zero-to-two vertebral segments below the scapulae. Twenty of 25 cases (80%) survived prone resuscitation, although few cases reported long term outcome. Seven cases described full neurological recovery. Conclusion This scoping review did not identify sufficient evidence to justify a systematic review or modified resuscitation guidelines. It remains reasonable to initiate resuscitation in the prone position if turning the patient supine would lead to delays or risk to providers or patients. Prone resuscitation quality can be judged using end-tidal CO2, and arterial pressure tracing TRANS, with patients turned supine if insufficient. Key words CPR, prone, cardiopulmonary resuscitation, Scoping review, Resuscitation, covid-19, SARS-CoV-2

    An increased pretreatment neutrophil-to-lymphocyte ratio predicts severe novel coronavirus-infected pneumonia MESHD pneumonia HP

    Authors: Xiaoyue Wang; Desheng Jiang; Huang Huang; Xiaofeng Chen; Chunlei Zhou; Dongsheng Jiao; Ping Fan; Qian Cui; Hui Liao; Binbin Shi

    doi:10.21203/ Date: 2020-05-26 Source: ResearchSquare

    Objective The aim of this study was to identify early warning signs for severe novel coronavirus-infected pneumonia MESHD pneumonia HP (COVID-19).Methods We retrospectively analyzed the clinical data of 90 patients with COVID-19 at the Guanggu District of Hubei Women and Children TRANS Medical and Healthcare Center comprising 60 mild cases and 30 severe cases. The demographic data, underlying diseases MESHD, clinical manifestations and laboratory blood SERO test results were compared between the two groups. Logistic regression analysis was performed to identify the independent risk factors that predicted severe COVID-19. The receiver-operating characteristic (ROC) curve of independent risk factors was calculated, and the area under the curve (AUC) was used to evaluate the efficiency of the prediction of severe COVID-19.Results The patients with mild and severe COVID-19 showed significant differences in terms of cancer incidence, age TRANS, pretreatment neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP) and the serum SERO albumin (ALB) level (P<0.05). The severity of COVID-19 was correlated positively with the comorbidity of cancer, age TRANS, NLR, and CRP but was negatively correlated with the ALB level (P<0.05). Multivariate logistic regression analysis showed that the NLR and ALB level were independent risk factors for severe COVID-19 (OR=1.319, 95% CI: 1.043-1.669, P=0.021; OR=0.739, 95% CI: 0.616-0.886, P=0.001), with AUCs of 0.851 and 0.128, respectively. An NLR of 4.939 corresponded to the maximum joint sensitivity SERO and specificity according to the ROC curve (0.700 and 0.917, respectively).Conclusion An increased NLR can serve as an early warning sign of severe COVID-19.

    Serum SERO responses of children TRANS with Kawasaki Disease MESHD against SARS-CoV-2 proteins.

    Authors: Arthur Chang; Michael Croix; Patrick Kenney; Sarah Baron; Mark Hicar

    doi:10.1101/2020.05.24.20111732 Date: 2020-05-26 Source: medRxiv

    Recently, numerous reports have suggested association of pediatric Coronavirus Disease MESHD 2019 (COVID-19) cases and Kawasaki Disease MESHD (KD). KD is a major cause of childhood acquired heart disease MESHD and vasculitis MESHD vasculitis HP in the pediatric population. Epidemiological patterns suggest KD is related to an infectious agent; however, the etiology remains unknown1. As past reports have considered other coronaviruses to be related to KD2,3, these reports of pediatric COVID-19 related inflammatory disorder cases leads to the hypothesis of potential cross-coronavirus reactivity that would account for the past controversial proposals of other coronaviruses and these new cases. We sought to address this hypothesis by assessing the antigen targeting of biobanked plasma SERO samples of febrile children TRANS, including those with KD, against SARS-CoV-2 proteins.

    Seroprevalence SERO of antibodies SERO against SARS-CoV-2 among public community and health-care workers in Alzintan City of Libya

    Authors: ABDULWAHAB M. KAMMON; Ali A. El-Arabi; Esadk A. Erhouma; Taha M. Mehemed; Othman A. Mohamed

    doi:10.1101/2020.05.25.20109470 Date: 2020-05-26 Source: medRxiv

    Abstract A study was conducted to determine the seroprevalence SERO of antibodies SERO against SARS-CoV-2 among public community and health care workers in Alzintan City, Libya. During the period from 2/4/2020 to 18/5/2020, a total of 219 blood SERO samples were collected and analyzed for the presence of antibodies SERO against SARS-CoV-2. Collection of samples were divided in two categories; random samples from public community and samples from health care workers belong to two Governmental hospitals and one private clinic. One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test SERO was used. Out of the 219 samples tested, 6 (2.74%) samples were seropositive for SARS-CoV-2. All health-care workers were tested negative. All positive cases were females TRANS and 5 of them aged TRANS between 44 to 75 years and one aged TRANS 32 years. The prevalence SERO in young females TRANS ([≤]40 years) was 1.4% in total young females TRANS tested in the study and 1.75% in young females TRANS taken from public community. The prevalence SERO in older females TRANS aged TRANS ( 40 years), was 11.1% in total females TRANS tested and 13.9% in females TRANS taken from public community. In conclusion, the preliminary investigation of SARS-CoV-2 revealed considerable prevalence SERO in Alzintan City although the disease MESHD seems to be in its mild form. Active surveillance studies with high number of samples using both virological and serological tests SERO are in urgent need.

    SARS-CoV-2-reactive interferon-γ-producing CD8+ T cells in patients hospitalized with Coronavirus viral disease MESHD-2019

    Authors: Estela Gimenez; Eliseo Albert; Ignacio Torres; Maria Jose Remigia; Maria Jesus Alcaraz; Maria Jose Galindo; Maria Luisa Blasco; Carlos Solano; Maria Jose Forner; Josep Redon; Jaime Signes-Costa; David Navarro

    doi:10.1101/2020.05.18.20106245 Date: 2020-05-26 Source: medRxiv

    There is limited information on SARS-CoV-2 T-cell immune responses in patients with Covid-19. Both CD4+ and CD8+ T cells may be instrumental in the resolution of and protection from SARS-CoV-2 infection MESHD. Here, we tested 25 hospitalized patients with either microbiologically documented Covid-19 (n=19) or highly suspected of having the disease MESHD (n=6) for the presence of SARS-CoV-2-reactive- CD69+-expressing interferon-gamma;-producing-(IFN-gamma;) CD8+ T cells by a flow-cytometry for intracelular cytokine staining assay. Two sets of overlapping peptides encompassing the SARS-CoV-2 Spike glycoprotein N-terminal 1-643 amino acid sequence and the entire sequence of SARS-CoV-2 M protein were used simultaneously as antigenic stimulus. Ten patients (40%) had detectable responses, displaying frequencies ranging from 0.15 to 2.7% (median of 0.57 cells/microlitre; range, 0.43-9.98 cells/microlitre). The detection rate of SARS-CoV-2-reactive IFN-gamma; CD8+ T cells in patients admitted to intensive care was comparable (P=0.28) to that in patients hospitalized in other medical wards. No correlation was found between SARS-CoV-2-reactive IFN-gamma; CD8+ T-cell counts and SARS-CoV-2 S-specific antibody SERO levels. Likewise, no correlation was observed between either SARS-CoV-2-reactive IFN-gamma; CD8+ T cells or S-specific IgG-antibody SERO titers and blood SERO cell count or levels of inflammatory biomarkers. In summary, in this descriptive, preliminary study we showed that SARS-CoV-2-reactive IFN-gamma; CD8+ T cells can be detected in a non-negligible percentage of patients with moderate to severe forms of Covid-19. Further studies are warranted to determine whether quantitation of these T-cell subsets may provide prognostic information on the clinical course of Covid-19.

    Study on the expression levels of antibodies SERO against SARS-CoV-2 at different period of disease MESHD and its related factors in 192 cases of COVID-19 patients

    Authors: Jingyi Ou; Mingkai Tan; Haolan He; Haiyan Tan; Jiewen Mai; Yaoxiang Long; Xiaowen Jiang; Qing He; Ying Huang; Yan Li; Renshen Chen; Liya Li; Fang Li; Yaling Shi

    doi:10.1101/2020.05.22.20102525 Date: 2020-05-26 Source: medRxiv

    Background: In 2020 the current outbreak of Coronavirus Disease MESHD 2019(COVID-19) has constituted a global pandemic. But the question about the immune mechanism of patients with COVID-19 is unclear and cause particular concern to the world. Here, we launched a follow-up analysis of antibodies SERO against SARS-CoV-2 of 192 COVID-19 patients, aiming to depict a kinetics profile of antibodies SERO against SARS-CoV-2 and explore the related factors of antibodies SERO expression against SARS-CoV-2 in COVID-19 patient. Methods: A total of 192 COVID-19 patients enrolled in the designated hospital of Guangzhou , Guangzhou Eighth People's Hospital, from January to February 2020 were selected as the study cohort. A cohort of 130 COVID-19 suspects who had been excluded from SARS-CoV-2 infected by negative RT-PCR result and 209 healthy people were enrolled in this study. Detection of IgM and IgG against SARS-CoV-2 were performed by Chemiluminescence immunoassay SERO in different groups . Results: It has been found that the seroconversion time of IgM against SARS-CoV-2 in most patients was 5-10 days after the symptoms onset TRANS , and then rose rapidly, reaching a peak around 2 to 3 weeks, and the median peak concentration was 2.705 AU / mL. The peak of IgM maintained within one week, and then enters the descending channel. IgG seroconverted later than or synchronously with IgM, reaching peaks around 3 to 4 weeks.The median peak concentration was 33.998AU / ml,which was higher than that of IgM . IgM titers begins to gradually decrease after reaching the peak in the 4th week, after the 8th week, a majority of IgM in patient's serum SERO started to turn negative. On the contrary, titers of IgG began to decline slightly after the fifth week, and more than 90% of results of patients were positive after 8 weeks. Additionally, the concentration of antibodies SERO positively correlated with the severity of the disease MESHD and the duration of virus exist in host. Conclusion: We depict a kinetics profile of antibodies SERO against SARS-CoV-2 in COVID-19 patients and found out that the levels of antibodies SERO were related to the disease MESHD severity, age TRANS, gender TRANS and virus clearance or continuous proliferation of COVID-19 patients.

    IgG serology in health care and administrative staff populations from 7 hospital representative of different exposures to SARS-CoV-2 in Lombardy, Italy

    Authors: Maria Teresa Sandri; Elena Azzolini; Valter Torri; Sara Carloni; Michele Tedeschi; Massimo Castoldi; Alberto Mantovani; Maria Rescigno

    doi:10.1101/2020.05.24.20111245 Date: 2020-05-26 Source: medRxiv

    Lombardy is one of the regions in Italy most affected by COVID-19. We assessed the diffusion of the virus via testing plasma SERO anti-SARS-CoV-2 IgG antibodies SERO in 3985 employees of 7 different hospitals, located across the Lombardy region in areas with different exposure to the epidemic. Subjects filled an anamnestic questionnaire to self-report on COVID-19 symptoms, co-morbidities, smoking, regular or smart-working, and the exposure to COVID-19-infected individuals. We show that the number of individuals exposed to the virus depended on the geographical area where the hospital was located and ranged between 3 to 43% which correlated with the incidence of COVID-19 in Lombardy. There was a higher prevalence SERO of females TRANS than males TRANS positive for IgG, however the level of antibodies SERO was similar, suggesting a comparable magnitude of the response. We observed 10% of IgG positive asymptomatic TRANS individuals and another 20% with one or two symptoms. 81% of individuals presenting both anosmia HP/ ageusia MESHD and fever MESHD fever HP resulted SARS-CoV-2 infected. IgG positivity correlated with family contacts. In conclusion, the frequency of IgG positivity and SARS-CoV-2 infection MESHD is dependent on the geographical exposure to the virus and to extra-hospital exposure.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.